---
title: Autoimmune Encephalitis
description: Autoimmune encephalitis - antibody testing, tumor workup, first and second-line immunotherapy, and long-term management.
version: "1.0"
setting: ED, HOSP, ICU
status: draft
tags:
  - autoimmune
  - encephalitis
  - emergency
  - neurocritical-care
---

<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

# Autoimmune Encephalitis

**VERSION:** 1.0
**CREATED:** January 24, 2026
**REVISED:** January 24, 2026
**STATUS:** Draft - Pending Review

---

**DIAGNOSIS:** Autoimmune Encephalitis

**ICD-10:** G04.81 (Other encephalitis and encephalomyelitis, autoimmune), G04.90 (Encephalitis and encephalomyelitis, unspecified), G13.1 (Other systemic atrophy primarily affecting CNS in neoplastic disease)

**SCOPE:** Evaluation and management of autoimmune encephalitis in adults, including antibody-mediated (anti-NMDAR, LGI1, CASPR2, GABA-B, AMPA, etc.) and paraneoplastic encephalitis. Covers diagnostic workup, tumor screening, first-line and second-line immunotherapy, and long-term management. Excludes infectious encephalitis, Hashimoto's encephalopathy (SREAT), and pediatric-specific presentations.

**CLINICAL SYNONYMS:** Limbic encephalitis, anti-NMDA receptor encephalitis, paraneoplastic encephalitis, antibody-mediated encephalitis, voltage-gated potassium channel complex encephalitis (VGKC)

---

**KEY CLINICAL FEATURES:**
- **Subacute onset:** Days to weeks (usually <3 months)
- **Psychiatric symptoms:** Psychosis, paranoia, personality change, agitation, catatonia
- **Cognitive dysfunction:** Memory impairment (especially short-term), confusion
- **Seizures:** New-onset seizures (often refractory)
- **Movement disorders:** Orofacial dyskinesia, choreoathetosis, dystonia, catatonia
- **Autonomic instability:** Hyperthermia, blood pressure fluctuations, tachycardia, hypoventilation
- **Decreased level of consciousness:** May progress to coma

**MAJOR ANTIBODY SYNDROMES:**

| Antibody | Clinical Features | Tumor Association | Demographics |
|----------|-------------------|-------------------|--------------|
| **Anti-NMDAR** | Psychiatric, seizures, movement disorder, autonomic instability, coma | Ovarian teratoma (50% in women) | Young women > men |
| **Anti-LGI1** | Faciobrachial dystonic seizures, hyponatremia, memory loss | Thymoma (<10%) | Older adults (>50) |
| **Anti-CASPR2** | Neuromyotonia, limbic encephalitis, Morvan syndrome | Thymoma (20%) | Older men |
| **Anti-GABA-B** | Limbic encephalitis, prominent seizures | SCLC (50%) | Older adults |
| **Anti-AMPA** | Limbic encephalitis, psychiatric symptoms | SCLC, thymoma, breast (65%) | Older adults |
| **Anti-GAD65** | Stiff person, cerebellar, limbic encephalitis | Rare | F > M |
| **Anti-Hu (ANNA-1)** | Limbic encephalitis, sensory neuropathy, cerebellar | SCLC (majority) | Older adults |
| **Anti-Ma2/Ta** | Limbic/brainstem encephalitis, sleep disorder | Testicular, SCLC, breast | Young men (testicular) |

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

!!! danger "⚡ TREATABLE CAUSE OF ENCEPHALITIS"
    **Autoimmune encephalitis is treatable but time-sensitive.** Earlier immunotherapy leads to better outcomes. Do not wait for antibody results to start treatment if clinical suspicion is high.

!!! warning "⚠️ TUMOR SEARCH CRITICAL"
    Many autoimmune encephalitides are paraneoplastic. **Tumor identification and treatment** are essential for neurological recovery.

---

═══════════════════════════════════════════════════════════════
SECTION A: ACTION ITEMS
═══════════════════════════════════════════════════════════════

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| CBC with differential | Infection screen, baseline | Normal | STAT | STAT | — | STAT |
| CMP (BMP + LFTs) | Electrolytes (hyponatremia in LGI1), renal/hepatic function | Na+ <135 suggests LGI1; otherwise normal | STAT | STAT | — | STAT |
| TSH | Hashimoto's encephalopathy differential | Normal | URGENT | ROUTINE | — | URGENT |
| Blood glucose | Metabolic encephalopathy screen | Normal | STAT | STAT | — | STAT |
| ESR, CRP | Inflammatory markers | Usually normal or mildly elevated | URGENT | ROUTINE | — | URGENT |
| PT/INR, PTT | Pre-LP | INR <1.5 | STAT | STAT | — | STAT |
| HIV antibody/antigen | Immunocompromise screen | Negative | — | ROUTINE | — | ROUTINE |
| RPR/VDRL | Neurosyphilis differential | Negative | — | ROUTINE | — | ROUTINE |
| Urinalysis, urine drug screen | Alternative diagnoses | Negative | STAT | ROUTINE | — | STAT |
| Ammonia | Metabolic encephalopathy | Normal | URGENT | ROUTINE | — | URGENT |
| B12, folate | Metabolic causes of encephalopathy | Normal | — | ROUTINE | — | ROUTINE |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| **Autoimmune encephalitis panel (serum)** | Antibody identification | Identify specific antibody (NMDAR, LGI1, CASPR2, GABA-B, AMPA, GAD65, others) | — | STAT | — | STAT |
| **Paraneoplastic panel (serum)** | Tumor-associated antibodies | Identify Hu, Yo, Ri, Ma2/Ta, CV2, amphiphysin | — | STAT | — | STAT |
| TPO antibodies | Hashimoto's encephalopathy | Document if elevated | — | ROUTINE | — | ROUTINE |
| Anti-thyroglobulin antibodies | Hashimoto's encephalopathy | Document if elevated | — | ROUTINE | — | ROUTINE |
| ANA, dsDNA | Autoimmune disease screen | Usually negative | — | ROUTINE | — | ROUTINE |
| ANCA | Vasculitis screen | Negative | — | ROUTINE | — | ROUTINE |
| Tumor markers (CEA, AFP, CA-125, CA 19-9, beta-hCG, PSA) | Occult malignancy | Normal | — | ROUTINE | — | ROUTINE |
| Serum protein electrophoresis | Paraproteinemia | Normal | — | ROUTINE | — | ROUTINE |
| Quantitative immunoglobulins | Pre-IVIg, immunodeficiency | IgA >7 mg/dL | — | URGENT | — | URGENT |
| Hepatitis B surface antigen | Pre-rituximab screening | Negative | — | ROUTINE | — | ROUTINE |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Cell-based assay for neuronal antibodies | More sensitive than commercial panels | Antibody confirmation | — | EXT | — | EXT |
| VGCC antibodies (P/Q and N-type) | LEMS, cerebellar degeneration | Negative unless paraneoplastic | — | EXT | — | EXT |
| SOX1 antibody | SCLC-associated | Document | — | EXT | — | EXT |
| DPPX antibody | GI symptoms + encephalopathy | Document | — | EXT | — | EXT |
| Neurexin-3 antibody | Encephalitis, seizures | Document | — | EXT | — | EXT |
| IgLON5 antibody | Sleep disorder, brainstem dysfunction | Document | — | EXT | — | EXT |
| Mitochondrial DNA testing | Mitochondrial encephalopathy | Normal | — | EXT | — | EXT |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI brain with and without contrast | STAT | Medial temporal T2/FLAIR hyperintensity (limbic); may be normal in 50% | Hemodynamic instability, pacemaker | STAT | STAT | — | STAT |
| EEG (routine or continuous) | STAT if seizures or AMS | Extreme delta brush (NMDAR), temporal slowing, seizures | None | STAT | STAT | — | STAT |
| CT chest/abdomen/pelvis with contrast | Tumor search | Occult malignancy (lung, ovary, testes, thymus) | Contrast allergy, renal impairment | — | URGENT | — | URGENT |

**MRI Findings:**
- **Limbic encephalitis:** Medial temporal lobe T2/FLAIR hyperintensity (uni- or bilateral)
- **Anti-NMDAR:** Often normal; may show subtle cortical/subcortical changes
- **May be normal in up to 50%:** Does NOT rule out autoimmune encephalitis

**EEG Findings:**
- **Extreme delta brush:** Highly specific for anti-NMDAR encephalitis (seen in ~30%)
- **Temporal slowing:** Common in limbic encephalitis
- **Subclinical seizures:** Frequent; continuous EEG recommended

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| Pelvic ultrasound (women) | If anti-NMDAR positive | Ovarian teratoma | None | — | URGENT | — | URGENT |
| MRI pelvis with contrast | If US equivocal | Ovarian teratoma | Pacemaker | — | URGENT | — | URGENT |
| Testicular ultrasound (men <50) | If anti-Ma2 or clinical concern | Testicular tumor | None | — | URGENT | — | URGENT |
| CT or PET-CT chest | Thymoma, lung cancer | Tumor identification | Contrast allergy | — | URGENT | — | URGENT |
| Whole body PET-CT | Occult malignancy search | Any FDG-avid tumor | Hemodynamic instability | — | URGENT | — | URGENT |
| Mammogram | Breast cancer screening | Normal | None | — | ROUTINE | — | ROUTINE |
| Continuous EEG (cEEG) | Refractory cases, coma | Nonconvulsive seizures | None | — | STAT | — | STAT |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| Brain biopsy | Diagnostic uncertainty, refractory | Inflammatory infiltrate | Coagulopathy | — | EXT | — | EXT |
| FDG-PET brain | Clarify extent of involvement | Temporal hypermetabolism | Hemodynamic instability | — | EXT | — | EXT |
| Repeat whole body imaging | If initial negative, strong suspicion | Occult tumor | — | — | EXT | — | EXT |

### LUMBAR PUNCTURE

**Indication:** ALL suspected autoimmune encephalitis

**Timing:** URGENT after CT (or proceed directly if no contraindications)

**Volume Required:** 15-20 mL (need adequate volume for antibody testing)

| Study | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|-------|-----------|----------------|:--:|:----:|:---:|:---:|
| Opening pressure | Usually normal | 10-20 cmH2O | URGENT | STAT | — | STAT |
| Cell count with differential | Lymphocytic pleocytosis | WBC 10-100 (lymphocyte predominant); may be normal | URGENT | STAT | — | STAT |
| Protein | Often mildly elevated | 45-100 mg/dL; may be normal | URGENT | STAT | — | STAT |
| Glucose | Usually normal | Normal | URGENT | STAT | — | STAT |
| **Autoimmune encephalitis panel (CSF)** | **Critical for diagnosis** | **Identify neuronal antibodies; CSF more sensitive than serum for some (NMDAR)** | **STAT** | **STAT** | — | **STAT** |
| Oligoclonal bands | Intrathecal synthesis | May be positive | — | ROUTINE | — | ROUTINE |
| IgG index | Intrathecal synthesis | May be elevated | — | ROUTINE | — | ROUTINE |
| HSV PCR | Exclude HSV encephalitis | Negative (but post-HSV autoimmune is possible) | STAT | STAT | — | STAT |
| VZV PCR | Exclude VZV encephalitis | Negative | STAT | STAT | — | STAT |
| Bacterial culture, Gram stain | Exclude bacterial infection | Negative | STAT | STAT | — | STAT |
| Cytology | Carcinomatous meningitis | Negative | — | ROUTINE | — | ROUTINE |
| BioFire ME Panel | Exclude infectious causes | Negative | STAT | STAT | — | STAT |

**CSF Findings in Autoimmune Encephalitis:**

| Parameter | Typical Finding |
|-----------|-----------------|
| Opening pressure | Normal |
| WBC | Normal to mild pleocytosis (10-100, lymphocytes) |
| Protein | Normal to mildly elevated |
| Glucose | Normal |
| Oligoclonal bands | May be positive |
| Neuronal antibodies | Positive (CSF more sensitive for NMDAR) |

**CRITICAL:** CSF may be completely normal in autoimmune encephalitis. A normal CSF does NOT rule out the diagnosis.

**Special Handling:** Send adequate volume (15-20 mL). CSF autoimmune panel sent to reference lab; results may take 1-2 weeks.

---

## 3. TREATMENT

**CRITICAL:** Start immunotherapy empirically if clinical suspicion high. Do NOT wait for antibody results (may take 1-2 weeks).

### When to Start Empiric Immunotherapy

**Start empiric treatment when ALL of the following are met:**
1. Clinical presentation meets criteria for "possible autoimmune encephalitis" (subacute onset, encephalopathy, plus seizures/CSF pleocytosis/MRI findings)
2. Infectious etiologies reasonably excluded (negative CSF bacterial culture/Gram stain, HSV PCR sent or negative)
3. Alternative diagnoses (toxic, metabolic, structural) reasonably excluded

**Escalate urgency for empiric treatment if:**
- Severe presentation (ICU admission, status epilepticus, coma)
- Rapidly progressive course
- Classical syndrome (e.g., young woman with psychiatric symptoms + movement disorder → anti-NMDAR)

**Reference:** [Canadian Consensus Guidelines](https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/canadian-consensus-guidelines-for-the-diagnosis-and-treatment-of-autoimmune-encephalitis-in-adults/DC88204486B656B85324E93AF2CCCFC7); [Cellucci et al. 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC8223680/)

### 3A. First-Line Immunotherapy

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Methylprednisolone | IV | First-line immunotherapy | 1000 mg daily x 5 days :: IV :: daily x 5 days :: 1000 mg IV daily x 3-5 days; infuse over 1 hour | Active untreated infection, uncontrolled diabetes (relative) | Glucose, BP, psychiatric symptoms, GI bleeding | — | STAT | — | STAT |
| IVIg (immune globulin IV) | IV | First-line immunotherapy | 0.4 g/kg/day x 5 days :: IV :: daily x 5 days :: 0.4 g/kg/day IV for 5 days (total 2 g/kg); start slow day 1 | IgA deficiency with anti-IgA antibodies; severe renal impairment | Renal function, headache, infusion reactions | — | STAT | — | STAT |
| Plasmapheresis (PLEX) | — | First-line immunotherapy | 5-7 exchanges over 10-14 days :: — :: QOD :: 5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange | Hemodynamic instability, severe sepsis | BP, electrolytes, coagulation, fibrinogen | — | STAT | — | STAT |

**First-Line Strategy:**
- **High-dose steroids + IVIg:** Most common initial approach
- **PLEX:** Alternative or in combination with steroids
- **Combination:** Steroids + IVIg OR Steroids + PLEX often used together
- **Response time:** May take 2-4 weeks; if no improvement, proceed to second-line

### 3B. Second-Line Immunotherapy (If First-Line Fails)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Rituximab | IV | First-line failure, anti-NMDAR | 375 mg/m² weekly x 4 weeks; 1000 mg x 2 doses :: IV :: weekly x 4 or 1000 mg q2wk x 2 :: 375 mg/m² IV weekly x 4 OR 1000 mg IV x 2 doses (2 weeks apart); pre-medicate | Active infection, HBV (screen), live vaccines | Infusion reactions, B-cell counts, immunoglobulins | — | URGENT | — | URGENT |
| Cyclophosphamide | IV | First-line failure, paraneoplastic | 750 mg/m² monthly x 6 :: IV :: monthly :: 750 mg/m² IV monthly x 6 cycles; with mesna for bladder protection | Cytopenias, active infection, pregnancy | CBC weekly, renal function, hemorrhagic cystitis | — | URGENT | — | URGENT |

**Second-Line Timing:**
- **Standard:** Consider at 2-4 weeks if no response to first-line
- **Critically ill (ICU, coma, refractory status epilepticus):** Consider second-line agents at 1-2 weeks if no improvement, or sooner if rapidly deteriorating
- **Early escalation considerations:** Disease severity, initial treatment response, and relapse risk
- **Practical note:** Given delayed onset of rituximab effect (weeks), continue first-line therapies until clinical improvement observed
- Earlier in severe/refractory cases (persistent coma, ICU-level care)
- Rituximab preferred for anti-NMDAR encephalitis
- Cyclophosphamide often preferred for paraneoplastic encephalitis

### 3C. Tumor Treatment

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Tumor resection (ovarian teratoma) | Surgical | Anti-NMDAR with teratoma | N/A :: — :: :: Surgical removal of ovarian teratoma is CRITICAL for recovery; early surgery improves outcomes | Unstable patient | Post-op neuro status | — | URGENT | — | URGENT |
| Thymectomy | Surgical | Thymoma-associated encephalitis | N/A :: — :: :: Surgical resection of thymoma | Unstable patient | Post-op neuro status | — | ROUTINE | — | ROUTINE |
| Oncology treatment | Various | Tumor-associated encephalitis | Per oncology :: — :: :: Treat underlying malignancy per oncology recommendations | — | Per oncology | — | ROUTINE | — | ROUTINE |

**CRITICAL:** Tumor removal is essential for neurological recovery in paraneoplastic cases. Early surgery (especially teratoma removal) significantly improves outcomes.

### 3D. Seizure Management

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Levetiracetam | IV/PO | Seizures, seizure prophylaxis | 1000 mg BID; 1500 mg BID; 2000 mg BID :: IV/PO :: BID :: Load 1000-2000 mg IV, then 1000-1500 mg BID; may need higher doses | Severe renal impairment (adjust) | Seizure frequency, behavior | STAT | STAT | — | STAT |
| Lacosamide | IV/PO | Adjunctive seizure control | 200 mg BID; 300 mg BID :: IV/PO :: BID :: Load 200-400 mg IV, then 200-300 mg BID | PR prolongation, severe cardiac disease | ECG, PR interval | — | STAT | — | STAT |
| Valproate | IV/PO | Seizures | 20 mg/kg load; 500 mg BID; 750 mg BID :: IV/PO :: load then BID :: Load 20-30 mg/kg IV, then 500-750 mg BID; target level 50-100 | Liver disease, mitochondrial disease, pregnancy | LFTs, ammonia, levels | STAT | STAT | — | STAT |
| Lorazepam | IV | Acute seizure termination | 2 mg; 4 mg :: IV :: PRN :: 0.1 mg/kg IV (max 4 mg); may repeat x1 | Respiratory depression | RR, O2 sat | STAT | STAT | — | STAT |
| Midazolam infusion | IV | Refractory status epilepticus | 0.1-0.4 mg/kg/hr :: IV :: continuous :: 0.2 mg/kg bolus, then 0.1-0.4 mg/kg/hr infusion; for refractory seizures | — | EEG, sedation, respiratory | — | — | — | STAT |

### 3E. Symptomatic/Supportive Care

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Haloperidol | IV/IM | Agitation, psychosis | 2-5 mg q4-6h PRN :: IV/IM :: q4-6h PRN :: 2-5 mg IV/IM q4-6h PRN for severe agitation; avoid in movement disorders | QT prolongation, movement disorders, Parkinson | QTc, EPS | STAT | STAT | — | STAT |
| Quetiapine | PO | Agitation, psychosis (milder) | 25 mg BID; 50 mg BID; 100 mg BID :: PO :: BID :: Start 25 mg BID; titrate as needed; lower EPS risk | QT prolongation | QTc, sedation | — | ROUTINE | — | ROUTINE |
| Lorazepam | IV/PO | Catatonia, agitation | 1 mg q6h; 2 mg q6h :: IV/PO :: q6h :: 1-2 mg IV/PO q6h; often effective for catatonia | Respiratory depression | RR, sedation | STAT | STAT | — | STAT |
| Propranolol | PO | Autonomic instability (tachycardia) | 10 mg TID; 20 mg TID :: PO :: TID :: 10-20 mg PO TID for tachycardia | Bradycardia, hypotension, asthma | HR, BP | — | ROUTINE | — | ROUTINE |
| Clonidine | PO/transdermal | Autonomic instability | 0.1 mg BID; 0.1 mg patch weekly :: PO/TD :: BID :: 0.1 mg PO BID or 0.1 mg/24h patch; for hypertension/tachycardia | Hypotension | BP, HR | — | ROUTINE | — | ROUTINE |
| Enoxaparin | SC | DVT prophylaxis | 40 mg daily :: SC :: daily :: 40 mg SC daily | Active bleeding, coagulopathy | Platelet count | — | STAT | — | STAT |
| Famotidine | IV/PO | Stress ulcer prophylaxis | 20 mg BID :: IV/PO :: BID :: 20 mg BID if on steroids or intubated | None | GI bleeding | — | ROUTINE | — | ROUTINE |
| Insulin | IV/SC | Steroid-induced hyperglycemia | Per sliding scale :: IV/SC :: per protocol :: Target glucose <180 mg/dL | Hypoglycemia | Glucose q4-6h | — | ROUTINE | — | STAT |

### 3F. Long-Term/Maintenance Immunotherapy

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Mycophenolate mofetil | PO | Maintenance immunosuppression | 500 mg BID; 1000 mg BID; 1500 mg BID :: PO :: BID :: Start 500 mg BID; increase to 1000-1500 mg BID over 2-4 weeks | Pregnancy, cytopenias | CBC q2wk x 2 mo, then monthly | — | ROUTINE | ROUTINE | — |
| Azathioprine | PO | Maintenance immunosuppression | 50 mg daily; 100 mg daily; 150 mg daily :: PO :: daily :: Start 50 mg daily; increase by 50 mg q2-4wk to 2-3 mg/kg/day; check TPMT first | TPMT deficiency, pregnancy | CBC weekly x 4, then monthly; LFTs | — | ROUTINE | ROUTINE | — |
| Prednisone (oral taper) | PO | Steroid taper | 60 mg daily; 40 mg daily; 20 mg daily; 10 mg daily :: PO :: daily :: Taper over weeks to months; individualize based on response | — | Glucose, BP, bone density | — | ROUTINE | ROUTINE | — |
| Rituximab (maintenance) | IV | Relapse prevention (NMDAR) | 500-1000 mg q6mo :: IV :: q6 months :: 500-1000 mg IV q6 months for 2 years or longer; recheck antibodies | Active infection | B-cell counts, immunoglobulins | — | — | ROUTINE | — |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Neurology consult for diagnosis confirmation, immunotherapy guidance, and antibody interpretation | STAT | STAT | — | STAT |
| Neuro-immunology consult for complex cases, second-line therapy decisions, and long-term management | — | URGENT | ROUTINE | URGENT |
| Oncology consult for tumor workup and treatment if paraneoplastic syndrome identified | — | URGENT | — | URGENT |
| Gynecologic oncology for ovarian teratoma removal which is critical for anti-NMDAR encephalitis recovery | — | URGENT | — | URGENT |
| Critical care consult for ICU admission given autonomic instability, coma, or need for sedation/ventilation | STAT | STAT | — | STAT |
| Psychiatry consult for severe psychiatric symptoms, catatonia, or behavioral management in acute phase | — | URGENT | — | URGENT |
| Epilepsy consult for refractory seizures and continuous EEG monitoring guidance | — | URGENT | — | URGENT |
| Physical therapy for mobility assessment and fall prevention given fluctuating weakness and dyskinesias | — | ROUTINE | ROUTINE | ROUTINE |
| Occupational therapy for ADL assessment and cognitive rehabilitation to maximize functional recovery | — | ROUTINE | ROUTINE | ROUTINE |
| Speech therapy for swallow evaluation and communication strategies given dysarthria and aphasia | — | URGENT | ROUTINE | URGENT |
| Neuropsychology for formal cognitive assessment to document deficits and guide rehabilitation | — | — | ROUTINE | — |
| Social work for discharge planning and family support given prolonged recovery and potential disability | — | ROUTINE | ROUTINE | ROUTINE |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Return immediately if worsening confusion, seizures, or new symptoms develop (may indicate relapse requiring treatment escalation) | STAT | — | STAT |
| Continue immunotherapy as prescribed even when feeling better; stopping early increases relapse risk | — | STAT | STAT |
| Report fever or signs of infection promptly as immunosuppression increases infection risk | — | STAT | STAT |
| Follow seizure precautions including no driving, swimming alone, or heights due to unpredictable seizure risk | — | STAT | STAT |
| Attend all follow-up appointments as relapses can occur months to years after initial presentation | — | ROUTINE | ROUTINE |
| Expect that recovery may take months to years; improvement often continues for 2+ years | — | ROUTINE | ROUTINE |
| Participate in cognitive rehabilitation as this is essential for optimizing recovery from memory and executive deficits | — | ROUTINE | ROUTINE |
| Contact Autoimmune Encephalitis Alliance (www.aealliance.org) for patient support and educational resources | — | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Use fall precautions including walker and supervision due to movement disorders and cognitive impairment | STAT | STAT | STAT |
| Aspiration precautions including thickened liquids and upright positioning if swallow impaired | STAT | STAT | — |
| DVT prophylaxis with SCDs and/or anticoagulation given prolonged immobility risk | — | STAT | — |
| Avoid live vaccines while on immunosuppression; inactivated vaccines are safe and recommended | — | ROUTINE | ROUTINE |
| Practice infection prevention including hand hygiene and avoiding sick contacts while on immunosuppression | — | STAT | STAT |
| Continue regular cancer screening for paraneoplastic cases as tumor recurrence can trigger relapse | — | — | ROUTINE |
| Use cognitive pacing with scheduled rest periods to manage post-encephalitis fatigue | — | ROUTINE | ROUTINE |
| Do not drive until cleared by neurology due to seizure risk and cognitive impairment | — | STAT | STAT |

---

═══════════════════════════════════════════════════════════════
SECTION B: REFERENCE (Expand as Needed)
═══════════════════════════════════════════════════════════════

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| HSV encephalitis | Acute, temporal lobe predominant, hemorrhagic | MRI temporal, HSV PCR |
| Other viral encephalitis | Fever, CSF pleocytosis, specific epidemiology | Viral PCRs |
| Bacterial meningitis | Acute, toxic, PMN predominant CSF | CSF Gram stain, culture |
| Tuberculous meningitis | Subacute, basilar, low glucose | CSF AFB, PCR, ADA |
| Neurosyphilis | Risk factors, varied presentations | RPR, CSF VDRL, FTA-ABS |
| Primary CNS lymphoma | Immunocompromised, periventricular | MRI pattern, CSF cytology |
| Glioblastoma | Focal deficits, ring-enhancing mass | MRI, biopsy |
| Creutzfeldt-Jakob disease | Rapid dementia, myoclonus, DWI restriction | MRI pattern, 14-3-3, RT-QuIC |
| Hashimoto's encephalopathy (SREAT) | Elevated TPO, responds to steroids | TPO antibodies, exclusion |
| Psychiatric illness (primary) | No CSF/MRI changes, prior history | Normal workup, psychiatric evaluation |
| Toxic/metabolic encephalopathy | Drug/toxin exposure, metabolic derangement | Toxicology, metabolic panel |
| ADEM | Post-infectious, multifocal white matter | MRI pattern (multifocal), monophasic |
| CNS vasculitis | Multifocal strokes, systemic symptoms | Angiography, vessel wall MRI |
| Wernicke encephalopathy | Alcoholism, classic triad, mammillary bodies | Thiamine trial, MRI |
| Seizure-related (postictal) | Seizure witnessed, resolves with time | EEG, observation |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Neurological exam (GCS, MMSE) | q4-8h initially | Improving | Re-evaluate treatment, escalate | STAT | STAT | ROUTINE | STAT |
| Seizure activity | Continuous if cEEG; q4h assessment | No seizures | Escalate antiepileptic therapy | STAT | STAT | — | STAT |
| Vital signs (autonomic function) | q1-4h | Stable HR, BP, temp | Supportive care, ICU if unstable | STAT | STAT | — | STAT |
| Blood glucose | q6h if on steroids | <180 mg/dL | Insulin adjustment | — | ROUTINE | — | STAT |
| Renal function | q24-48h during IVIg | Cr stable | Hydration, adjust IVIg rate | — | ROUTINE | — | ROUTINE |
| Serum sodium | q12-24h (especially LGI1) | 135-145 mEq/L | Fluid restriction if hyponatremic | STAT | STAT | — | STAT |
| Antibody titers (serum/CSF) | q3-6 months | Decreasing | Consider treatment escalation | — | — | ROUTINE | — |
| Tumor surveillance | Per oncology | No recurrence | Oncology management | — | — | ROUTINE | — |
| B-cell counts (if on rituximab) | Before each infusion | Adequate depletion | Adjust dosing interval | — | — | ROUTINE | — |
| CBC (if on immunosuppression) | q1-4 weeks | Normal counts | Hold medication, infection workup | — | ROUTINE | ROUTINE | ROUTINE |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| **ICU admission** | GCS <12; refractory seizures; autonomic instability; need for intubation; coma; severe psychiatric symptoms requiring restraint |
| **Step-down/telemetry** | GCS 12-14; controlled seizures; stable autonomic function; receiving immunotherapy |
| **General floor** | GCS 15; stable; no seizures; able to participate in therapies; can complete immunotherapy |
| **Acute rehabilitation** | Significant cognitive or motor deficits; requires intensive therapy; medically stable |
| **Discharge home** | Significant improvement; safe swallow; adequate support; outpatient immunotherapy arranged; neurology follow-up scheduled |
| **Long-term care** | Severe persistent deficits; unable to live independently |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| First-line immunotherapy (steroids, IVIg, PLEX) | Class II, Level B | [Titulaer et al. Lancet Neurol 2013](https://pubmed.ncbi.nlm.nih.gov/23290630/) |
| Early immunotherapy improves outcomes | Class II, Level B | [Titulaer et al. Lancet Neurol 2013](https://pubmed.ncbi.nlm.nih.gov/23290630/) |
| Second-line therapy (rituximab, cyclophosphamide) | Class III, Level C | [Dalmau et al. Lancet Neurol 2019](https://pubmed.ncbi.nlm.nih.gov/31326280/) |
| Tumor removal essential for recovery | Class II, Level B | [Titulaer et al. Lancet Neurol 2013](https://pubmed.ncbi.nlm.nih.gov/23290630/) |
| CSF more sensitive than serum for NMDAR | Class II, Level B | [Gresa-Arribas et al. Lancet Neurol 2014](https://pubmed.ncbi.nlm.nih.gov/24275432/) |
| Extreme delta brush in anti-NMDAR | Class III, Level C | [Schmitt et al. Neurology 2012](https://pubmed.ncbi.nlm.nih.gov/22966581/) |
| LGI1 associated with hyponatremia and FBDS | Class II, Level B | [Irani et al. Brain 2010](https://pubmed.ncbi.nlm.nih.gov/20833645/) |
| Diagnostic criteria for autoimmune encephalitis | Consensus Guidelines | [Graus et al. Lancet Neurol 2016](https://pubmed.ncbi.nlm.nih.gov/26906964/) |
| Long-term outcomes and relapse risk | Class II, Level B | [Titulaer et al. Lancet Neurol 2013](https://pubmed.ncbi.nlm.nih.gov/23290630/) |

---

## CHANGE LOG

**v1.0 (January 24, 2026)**
- Initial template creation
- Comprehensive antibody syndrome table
- First and second-line immunotherapy protocols
- Tumor screening guidance
- Seizure and autonomic management
- Long-term maintenance therapy

---

## APPENDIX A: Graus 2016 Diagnostic Criteria for Autoimmune Encephalitis

**Possible Autoimmune Encephalitis (all 3 required):**
1. Subacute onset (<3 months) of working memory deficits, altered mental status, or psychiatric symptoms
2. At least ONE of:
   - New focal CNS findings
   - Seizures not explained by prior seizure disorder
   - CSF pleocytosis (>5 WBC/μL)
   - MRI features suggestive of encephalitis
3. Reasonable exclusion of alternative causes

**Definite Autoimmune Encephalitis:**
- Possible autoimmune encephalitis PLUS
- Positive neuronal antibody (serum or CSF)

**Probable Anti-NMDAR Encephalitis (all 3 required):**
1. Rapid onset (<3 months) of at least 4 of:
   - Abnormal behavior or cognitive dysfunction
   - Speech dysfunction
   - Seizures
   - Movement disorder, dyskinesias, or rigidity
   - Decreased level of consciousness
   - Autonomic dysfunction or central hypoventilation
2. At least ONE of:
   - Abnormal EEG
   - CSF pleocytosis or oligoclonal bands
3. Reasonable exclusion of alternative causes

---

## APPENDIX B: Tumor Screening by Antibody

| Antibody | Primary Tumor | Screening |
|----------|---------------|-----------|
| **Anti-NMDAR** | Ovarian teratoma (women) | Pelvic US → MRI pelvis if negative; repeat q6mo x 2 years |
| **Anti-LGI1** | Thymoma (rare) | CT chest |
| **Anti-CASPR2** | Thymoma (~20%) | CT chest |
| **Anti-GABA-B** | SCLC (~50%) | CT chest; PET-CT if negative |
| **Anti-AMPA** | SCLC, thymoma, breast | CT chest/abdomen; mammogram; PET-CT |
| **Anti-Hu (ANNA-1)** | SCLC (~80%) | CT chest; PET-CT if negative |
| **Anti-Yo** | Ovarian, breast | Pelvic US, mammogram, CT |
| **Anti-Ma2/Ta** | Testicular (young men), SCLC | Testicular US, CT chest |
| **Anti-CV2/CRMP5** | SCLC, thymoma | CT chest |
| **Anti-amphiphysin** | Breast, SCLC | Mammogram, CT chest |

**If initial screening negative but paraneoplastic suspected:**
- Repeat imaging in 3-6 months
- Consider whole-body PET-CT
- Continue surveillance for at least 5 years

---

## APPENDIX C: Treatment Algorithm

```
SUSPECTED AUTOIMMUNE ENCEPHALITIS
              │
              ▼
┌─────────────────────────────┐
│ 1. Exclude infections (HSV, │
│    bacterial, etc.)         │
│ 2. Send antibody panels     │
│    (serum AND CSF)          │
│ 3. MRI brain, EEG           │
│ 4. CT body for tumor        │
└─────────────────────────────┘
              │
              ▼
    High clinical suspicion?
         /          \
       YES           NO
        │             │
        ▼             ▼
┌──────────────┐  Wait for
│ START        │  antibody
│ FIRST-LINE:  │  results
│ • IV steroids│
│ • IVIg       │
│ • ± PLEX     │
└──────────────┘
        │
        ▼
   Response at 2-4 weeks?
         /          \
       YES           NO
        │             │
        ▼             ▼
┌──────────────┐ ┌──────────────┐
│ Continue     │ │ SECOND-LINE: │
│ maintenance  │ │ • Rituximab  │
│ therapy      │ │ • ± Cyclophos│
└──────────────┘ └──────────────┘
        │             │
        ▼             ▼
   TUMOR FOUND?   TUMOR FOUND?
        │             │
       YES           YES
        │             │
        ▼             ▼
   ┌─────────────────────┐
   │  TUMOR TREATMENT    │
   │  (Surgery, chemo,   │
   │   radiation)        │
   │  ESSENTIAL FOR      │
   │  NEUROLOGICAL       │
   │  RECOVERY           │
   └─────────────────────┘
```

---

## APPENDIX D: Prognosis by Antibody Type

| Antibody | Outcome | Relapse Rate | Notes |
|----------|---------|--------------|-------|
| **Anti-NMDAR** | Good with treatment (80% significant recovery) | 12-25% | Better if teratoma removed; relapses respond to treatment |
| **Anti-LGI1** | Good (70-80% respond) | 20-35% | Cognitive deficits may persist; hyponatremia improves |
| **Anti-CASPR2** | Moderate to good | Variable | May have associated neuromyotonia |
| **Anti-GABA-B** | Moderate (depends on tumor) | Low if tumor controlled | Prognosis linked to tumor |
| **Anti-AMPA** | Moderate to poor | High (>50%) | Often paraneoplastic; tumor treatment important |
| **Anti-Hu** | Poor | Low (progressive) | Usually paraneoplastic; neurological deficits often irreversible |
| **Anti-Yo** | Poor | Low (progressive) | Cerebellar degeneration usually irreversible |
| **Anti-Ma2** | Moderate | Variable | Better if testicular tumor found and treated |
